Considering the major role of VEGFR2 in VEGF-induced angiogenesis in human cancer, the finding of high VEGFR2 expression in Her2-positive breast cancer provides scientific rationale for studying the clinical activity of therapeutic blockade of VEGFR2 in the clinically aggressive breast cancer subtype 30, 38. This evidence concerns the gene KDR and breast carcinoma.